Co-Authors
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and YOSHITSUGU MITANI.
Connection Strength
5.518
-
Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clin Cancer Res. 2020 03 01; 26(5):1175-1184.
Score: 0.703
-
Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
Score: 0.533
-
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res. 2014 Dec 15; 20(24):6570-81.
Score: 0.493
-
MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome. PLoS One. 2013; 8(6):e66778.
Score: 0.450
-
Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res. 2011 Nov 15; 17(22):7003-14.
Score: 0.400
-
Expression and regulation of the ?N and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings. Am J Pathol. 2011 Jul; 179(1):391-9.
Score: 0.388
-
Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010 Oct 01; 16(19):4722-31.
Score: 0.369
-
Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers. Sci Rep. 2024 07 15; 14(1):16300.
Score: 0.242
-
Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2023 Jul 14; 29(14):2737.
Score: 0.226
-
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851.
Score: 0.221
-
Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations. Clin Cancer Res. 2021 07 15; 27(14):3960-3969.
Score: 0.195
-
Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2021 02 01; 27(3):852-864.
Score: 0.188
-
Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018 09 15; 124(18):3693-3705.
Score: 0.162
-
Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression. Mod Pathol. 2018 07; 31(7):1064-1072.
Score: 0.155
-
Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.151
-
Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. Am J Pathol. 2013 Jun; 182(6):2048-57.
Score: 0.111
-
Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance. Mod Pathol. 2024 Jan; 37(1):100371.
Score: 0.058
-
Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res. 2023 08 15; 29(16):3162-3171.
Score: 0.057
-
Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. J Pathol. 2023 11; 261(3):256-268.
Score: 0.057
-
Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. Cancers (Basel). 2022 Jul 28; 14(15).
Score: 0.053
-
LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 2021 May 14; 10(5):40.
Score: 0.049
-
Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma. Cancers (Basel). 2020 Aug 27; 12(9).
Score: 0.046
-
N-Terminal Truncated Myb with New Transcriptional Activity Produced Through Use of an Alternative MYB Promoter in Salivary Gland Adenoid Cystic Carcinoma. Cancers (Basel). 2019 Dec 21; 12(1).
Score: 0.044
-
Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget. 2018 Jan 26; 9(7):7341-7358.
Score: 0.038
-
Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. Oral Oncol. 2017 03; 66:38-45.
Score: 0.036
-
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
Score: 0.036
-
A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets. Oncotarget. 2014 Dec 30; 5(24):12528-42.
Score: 0.031
-
Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013 Jul; 123(7):2965-8.
Score: 0.028